Habush Habush & Rottier S.C. ® > Blog > Uncategorized > Baxter Halts Production of Multiple-Dose Heparin Due to Health Risk

Baxter Halts Production of Multiple-Dose Heparin Due to Health Risk

Posted under Uncategorized

The FDA announced today that Baxter Healthcare Corp. has voluntarily ceased production of multiple-dose vials of heparin after reports linking the drug to severe allergic reactions which have caused four deaths to date. Heparin, a blood-thinning drug, is used to treat blood clots in millions of patients nationwide, as well as being commonly administered just before certain types of surgery.

Up to now, only patients who were given heparin in “high bolus” doses over a short period of time have displayed adverse reactions, including nausea, vomiting, difficulty breathing, excessive sweating, and dangerously low blood pressure, which can lead to shock and death.

Today’s announcement follows a voluntary recall of nine lots of heparin by Baxter issued Jan. 17.

If you have been affected by a harmful drug or defective product, contact a Green Bay personal injury attorney from Habush Habush & Rottier S.C. ® at 800-757-8644 today.